IQVIA (NYSE:IQV) Rating Lowered to "Hold" at StockNews.com

IQVIA (NYSE:IQV - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday.

A number of other equities research analysts have also recently commented on IQV. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a "buy" rating and a $276.00 price target for the company. TD Cowen decreased their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a report on Tuesday, November 5th. Leerink Partners restated an "outperform" rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Evercore ISI cut their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Trading Up 0.1 %

Shares of NYSE:IQV traded up $0.20 during midday trading on Thursday, reaching $201.43. The company's stock had a trading volume of 822,837 shares, compared to its average volume of 1,177,509. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a 50 day moving average price of $220.36 and a two-hundred day moving average price of $226.57. The firm has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.44, a PEG ratio of 2.10 and a beta of 1.51.

Institutional Trading of IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of IQV. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in IQVIA during the second quarter valued at $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter worth $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the third quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the 2nd quarter valued at $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.